Remeglurant
Jump to navigation
Jump to search
Clinical data | |
---|---|
Other names | MRZ-8456 |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C17H15BrN4O |
Molar mass | 371.238 g·mol−1 |
3D model (JSmol) | |
| |
|
Remeglurant (INN ; developmental code name MRZ-8456) is a drug which acts as a selective antagonist of the mGlu5 receptor.[1][2][3] It is under development by Merz Pharmaceuticals for the treatment of drug-induced dyskinesia but no development has been reported since at least 2016.[3]
See also
References
- ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN): Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2). World Health Organization.
- ^ US 7985753, Danysz W, Dekundy A, Hechenberger M, Henrich M, Jatzke C, Nagel J, Parsons CG, Weil T, Fotins J, Gutcaits A, Kalvinsh I, Zemribo R, Kauss V, "Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators.", issued 4 August 2006, assigned to Merz Pharmaceuticals GmbH
- ^ a b "Remeglurant". Adis Insight. Springer Nature Switzerland AG.
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Isoquinolines
- MGlu5 receptor antagonists
- Organobromides
- Pyrimidines
- All stub articles
- Nervous system drug stubs